Saudi Central Bank Has $2.79 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Saudi Central Bank grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 90.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,284 shares of the biopharmaceutical company’s stock after purchasing an additional 4,408 shares during the quarter. Saudi Central Bank’s holdings in Alnylam Pharmaceuticals were worth $2,795,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. MV Capital Management Inc. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $25,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $27,000. Golden State Wealth Management LLC boosted its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $29,000. Finally, Manchester Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $266.11 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The company has a market cap of $35.61 billion, a price-to-earnings ratio of 49.46 and a beta of 0.31. The firm has a 50 day simple moving average of $258.70 and a 200 day simple moving average of $290.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the business earned ($0.51) earnings per share. The company’s revenue for the quarter was up 66.9% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on ALNY shares. Stifel Nicolaus decreased their target price on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Royal Bank Of Canada dropped their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Barclays dropped their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Finally, Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $386.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.